Exscientia
Financials
Estimates*
GBP | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 13.2m | 20.8m | 20.6m | 20.1m | 30.2m | 39.8m | 25.0m |
% growth | 10 % | 58 % | (1 %) | (3 %) | 50 % | 32 % | (37 %) |
EBITDA | (31.7m) | (43.0m) | (144m) | (144m) | (145m) | (140m) | (165m) |
% EBITDA margin | (240 %) | (207 %) | (697 %) | (717 %) | (479 %) | (352 %) | (659 %) |
Profit | (30.4m) | (37.3m) | (89.8m) | (146m) | (132m) | (138m) | - |
% profit margin | (230 %) | (180 %) | (436 %) | (727 %) | (437 %) | (347 %) | - |
EV / revenue | - | 57.8x | 2.5x | 19.3x | 11.2x | 3.6x | -0.3x |
EV / EBITDA | - | -27.9x | -0.4x | -2.7x | -2.3x | -1.0x | 0.1x |
R&D budget | 14.9m | 33.4m | 97.4m | 128m | - | - | - |
R&D % of revenue | 113 % | 161 % | 473 % | 640 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Spinout | ||
N/A | Growth Equity VC | ||
€15.0m | Series A | ||
* | €23.0m | Series B | |
$70.0m | Series C | ||
$4.2m | Grant | ||
$30.0m | Series C | ||
$525m Valuation: $1.0b 57.5x EV/LTM Revenues -23.9x EV/LTM EBITDA | Series D | ||
$1.5m | Grant | ||
N/A | $305m Valuation: $2.9b 166.7x EV/LTM Revenues -69.4x EV/LTM EBITDA | IPO | |
$160m | Private Placement non VC | ||
* | $2.3m | Grant | |
* | $688m Valuation: $688m | Acquisition | |
Total Funding | CAD920m |
Related Content
Recent News about Exscientia
EditExscientia is a technology-driven company specializing in the design and development of drugs using artificial intelligence (AI). The company operates in the pharmaceutical and biotechnology market, focusing on creating more effective medicines at a faster pace. Exscientia serves pharmaceutical companies, research institutions, and healthcare providers by leveraging AI to enhance drug discovery and development processes. The business model revolves around partnerships and collaborations with major pharmaceutical firms, where Exscientia provides its AI-driven solutions to accelerate drug development. Revenue is generated through milestone payments, licensing fees, and royalties from successfully developed drugs.
Keywords: AI, drug design, drug development, pharmaceutical, biotechnology, healthcare, partnerships, licensing, royalties, innovation.